ARCHIVES OF

THE BALKAN MEDICAL UNION

The official journal of the Balkan Medical Union, since 1935

Citation Abbreviation:

Arch Balk Med Union

Clinical utility of fractional exhaled nitric oxide in active pulmonary sarcoidosis

0
<Introduction. Fractional exhaled nitric oxide (FeNO) is an established biomarker of type 2 airway inflammation in asthma, but its clinical utility in sarcoidosis remains uncertain.
The objective of the study. The objective of the study was (i) to describe FeNO levels in active disease; (ii) to analyse the association between FeNO and blood eosinophilia, spirometric and plethysmographic parameters and radiographic stage; and (iii) to explore the relationship between FeNO and markers of small airway involvement, particularly mid- and distal expiratory flows.
Material and methods. We conducted a prospective observational study at a national reference centre for pulmonary diseases in Albania. During 2020–2024, 422 adults with pulmonary sarcoidosis were hospitalized; FeNO, spirometry, body plethysmography and serum angiotensin converting enzyme (SACE) were assessed in an analytic cohort of 139 patients with clinically active disease. FeNO was measured with a NIOX MINO analyser according to American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations. Associations between FeNO, blood eosinophils, radiographic stage (I–IV), lung function indices and small-airway flows were evaluated with correlation and subgroup analyses.
Results. The mean FeNO was 11.1±4.7 ppb (median 11 ppb; range 4–25 ppb), indicating generally low to intermediate levels. FeNO showed a moderate positive correlation with peripheral blood eosinophil percentage (r = 0.39, p = 0.01). FeNO values did not differ significantly across radiographic stages (p = 0.10) and were not significantly associated with forced expiratory volume in one second (FEV1), forced vital capacity (FVC), total lung capacity (TLC), residual volume (RV), intrathoracic gas volume (ITGV), RV/TLC ratio, or SACE. In a subgroup of 54 patients with documented small airway obstruction, FeNO correlated moderately and negatively with maximal expiratory flow at 25% (MEF25) (r = –0.40, p = 0.04), consistent with higher FeNO levels in patients with more pronounced distal airflow limitation.
Conclusions. FeNO values were generally low to intermediate and showed limited ability to reflect overall disease activity. FeNO may provide complementary information in patients with blood eosinophilia or small airway obstruction, but it should not be used as a stand-alone biomarker for assessing sarcoidosis activity.
Keywords: sarcoidosis, nitric oxide, respiratory function tests.
Address for correspondence: Eva MUJA
Catholic University “Our Lady of Good Counsel”
Address: Rruga Dritan Hoxha, Tirana, Albania
E-mail address: e.duraku@skzkm.al
Share.

Comments are closed.

Dilka E, Muja Duraku E, Simaku A, Kapisyzi. P Clinical utility of fractional exhaled nitric oxide in active pulmonary sarcoidosis. Arch Balk Med Union. 2026;61(2):238-243. https://doi.org/10.31688/ABMU.2026.61.2.11

Exit mobile version